The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2024 | Infection risk associated with BTKIs in CLL: a meta-analysis of clinical trials
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses a meta-analysis of clinical trials examining the infection risk in patients with chronic lymphocytic leukemia (CLL) who were treated with BTK inhibitors (BTKIs). She notes a potential bias in the analysis, as higher-risk patients were more likely to receive BTKI-based treatments. However, Dr Eichhorst concludes that continuous therapy with BTKIs may have a cumulative infection risk due to long treatment durations. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
